GSK acquired Chinese biotech Siran Biotechnology for $1 billion on May 7, 2026
The deal grants GSK worldwide exclusive rights to SA030, a long-acting siRNA oligonucleotide, excluding mainland China, Hong Kong, Macau, and Taiwan
SA030 is designed to induce weight loss while preserving lean muscle mass, addressing a key limitation of current GLP-1 drugs like Wegovy and Zepbound
SA030 recently entered Phase I trials and is being developed for metabolic and vascular risk across lung, liver, and kidney disease
The acquisition positions GSK to compete in the crowded obesity market with a differentiated approach using extrahepatic siRNA delivery technology
SiranBio's cutting-edge technology targets therapeutic areas like ALK7 that are not amenable to traditional small molecules or biologics